CareDx, Inc., incorporated on December 21, 1998, is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap) is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. AlloMap is a non-invasive method recommended in the International Society for Heart and Lung Transplantation (ISHLT) patient care guidelines for surveillance of heart transplant rejection in patients 15 years of age or older.
The Company is engaged in the development of additional products for transplant monitoring using various technologies, including AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. The Company initiated the DART trial, which is designed to establish clinical validation, or the clinical performance characteristics of dd-cfDNA in detecting clinical and sub-clinical rejection in kidney allograft recipients. DART is a multicenter observational study of kidney transplant recipients where blood specimens are drawn periodically after transplant during follow up visits and also after treatment for acute rejection. DART is also designed to demonstrate the correlation of dd-cfDNA to renal function through comparison to both serum creatinine and estimated glomerular filtration rate.
The Company's AlloMap test uses a sample of the patient's blood. AlloMap uses gene expression technology to aid in the identification of heart transplant recipients at low risk of rejection. The Company offers the AlloMap Score Variability (AMV) service, which provides complementary information to help personalize long-term care of heart transplant recipients.
3260 Bayshore Blvd
The company trades on NASDAQ exchange. The company headquarter is located in California, CA. The company was established in the 1998.| Ticker | CDNA |
| Long Name | CareDx, Inc. |
| Short Name | CareDx |